Sana Biotechnology Management
Management criteria checks 4/4
Sana Biotechnology's CEO is Steve Harr, appointed in Sep 2018, has a tenure of 6.08 years. total yearly compensation is $2.67M, comprised of 24.7% salary and 75.3% bonuses, including company stock and options. directly owns 3.98% of the company’s shares, worth $37.46M. The average tenure of the management team and the board of directors is 4.2 years and 5.2 years respectively.
Key information
Steve Harr
Chief executive officer
US$2.7m
Total compensation
| CEO salary percentage | 24.7% |
| CEO tenure | 6.1yrs |
| CEO ownership | 4.0% |
| Management average tenure | 4.2yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline
Jul 14We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate
Jul 12
Sana Biotechnology: Now In Overbought Territory
Mar 17Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)
Jan 11Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?
Dec 30Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 14Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?
May 26We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate
Dec 19Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 03Sana Biotechnology A Buy For Potential Cancer Therapies
Jun 27Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?
May 16Sana Biotechnology: Exciting Preclinical Science
Feb 12Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?
Oct 13Sana Biotechnology: Hypoimmune Cell Therapies
Jul 01Sana Biotechnology reports Q1 results
May 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$245m |
| Mar 31 2024 | n/a | n/a | -US$309m |
| Dec 31 2023 | US$3m | US$659k | -US$283m |
| Sep 30 2023 | n/a | n/a | -US$276m |
| Jun 30 2023 | n/a | n/a | -US$362m |
| Mar 31 2023 | n/a | n/a | -US$320m |
| Dec 31 2022 | US$4m | US$645k | -US$269m |
| Sep 30 2022 | n/a | n/a | -US$300m |
| Jun 30 2022 | n/a | n/a | -US$298m |
| Mar 31 2022 | n/a | n/a | -US$207m |
| Dec 31 2021 | US$1m | US$611k | -US$356m |
| Sep 30 2021 | n/a | n/a | -US$358m |
| Jun 30 2021 | n/a | n/a | -US$327m |
| Mar 31 2021 | n/a | n/a | -US$433m |
| Dec 31 2020 | US$7m | US$535k | -US$285m |
Compensation vs Market: Steve's total compensation ($USD2.67M) is about average for companies of similar size in the US market ($USD3.21M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
CEO
Steve Harr (54 yo)
6.1yrs
Tenure
US$2,671,662
Compensation
Dr. Steven D. Harr, also known as Steve, M.D., is President and Chief Executive Officer at Sana Biotechnology, Inc. since September 2018 and also serves as its Director since October 2018. He served as the...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.1yrs | US$2.67m | 3.98% $ 37.5m | |
| Executive VP & CFO | 6.1yrs | US$1.19m | 0.23% $ 2.2m | |
| Senior VP & Chief Technical Officer | less than a year | no data | no data | |
| Executive VP & Chief Scientific Officer | less than a year | no data | no data | |
| Executive VP | 2.1yrs | US$4.26m | 0.042% $ 392.5k | |
| Executive VP & Chief People Officer | 6.1yrs | no data | no data | |
| Head of Cell Engineering | less than a year | no data | no data | |
| Senior VP and Head of Clinical & Translational Science | no data | no data | no data | |
| Executive VP & Chief Business Officer | 6yrs | US$1.59m | 0.39% $ 3.7m | |
| Senior VP & Head of Hypoimmune Platform | 5.7yrs | no data | no data | |
| Senior VP & Head of T Cell Therapeutics | 4.2yrs | no data | no data | |
| Senior VP & Head of CNS Therapy | 4yrs | no data | no data |
4.2yrs
Average Tenure
56.5yo
Average Age
Experienced Management: SANA's management team is considered experienced (4.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6yrs | US$2.67m | 3.98% $ 37.5m | |
| Independent Director | 6yrs | US$294.80k | 0.0062% $ 58.6k | |
| Independent Director | 4.4yrs | US$314.80k | 0.0032% $ 30.0k | |
| Independent Director | 4.5yrs | US$302.30k | 0.091% $ 855.9k | |
| Independent Director | 6yrs | US$299.80k | 0.067% $ 631.3k | |
| Independent Director | 3.9yrs | US$314.80k | 0% $ 0 | |
| Vice Chairman | 5.9yrs | no data | 1.21% $ 11.4m | |
| Independent Chairman of the Board | 6yrs | US$354.80k | 2.6% $ 24.5m | |
| Independent Director | 3.8yrs | US$299.80k | 0.0090% $ 84.6k | |
| Independent Director | 3.8yrs | US$302.30k | 0% $ 0 |
5.2yrs
Average Tenure
62.5yo
Average Age
Experienced Board: SANA's board of directors are considered experienced (5.2 years average tenure).